Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this phase II clinical trial is to determine the safety and effect on survival of patients autologous dendritic cells pulsed with autologous tumor lysate as a treatment for low-grade glioma patients. Other goals of this study are to determine if the vaccine can cause an immune response against patients' cancer cells and slow the growth of their brain tumors


Clinical Trial Description

PRIMARY OBJECTIVES: I. To determine the 5-year progression-free survival (PFS), using intradermal injections of autologous dendritic cells harvested from peripheral blood precursors and pulsed (co-cultured) with tumor lysate derived from surgical tissues in patients with low-grade gliomas. SECONDARY OBJECTIVES: I. To monitor overall survival (OS), and cellular immune responses in brain tumor patients injected with tumor lysate-pulsed dendritic cells. OUTLINE: Patients receive tumor lysate-pulsed autologous dendritic cell vaccine intradermally (ID) on days 0, 14, and 28. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01635283
Study type Interventional
Source Jonsson Comprehensive Cancer Center
Contact
Status Completed
Phase Phase 2
Start date January 10, 2012
Completion date May 13, 2016

See also
  Status Clinical Trial Phase
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00238303 - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Phase 2
Completed NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Phase 1
Completed NCT00045708 - A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas Phase 1/Phase 2
Active, not recruiting NCT03890952 - Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma Phase 2
Terminated NCT01814813 - Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery Phase 2
Terminated NCT01575275 - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Phase 2
Terminated NCT01996527 - 3T MRI Biomarkers of Glioma Treatment Response Early Phase 1
Terminated NCT01103375 - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase 1
Completed NCT00459381 - Pazopanib in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT00016328 - CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Terminated NCT00006773 - Bortezomib in Treating Patients With Recurrent Glioma Phase 1
Completed NCT01806675 - 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Phase 1/Phase 2
Terminated NCT01148966 - Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors Phase 1
Completed NCT00492089 - Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Phase 2
Completed NCT01125046 - Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Phase 2
Completed NCT01894061 - NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Phase 2
Completed NCT01644955 - Carboplatin in Treating Patients With Recurrent High-Grade Gliomas Phase 1
Terminated NCT01269411 - RO4929097 in Treating Patients With Recurrent Invasive Gliomas Phase 1
Completed NCT00641706 - Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme Phase 2